Researchers estimate that expanding access to weight-loss drugs could save over 50,000 lives annually, reducing obesity rates ...

Leerink Partners analyst Michael Cherny has maintained their neutral stance on HIMS stock, giving a Hold rating yesterday. Michael ...

US pharmaceutical company Eli Lilly and Co recently announced a roughly $200 million expansion of its manufacturing site in ...

Analyst David Larsen from BTIG maintained a Buy rating on LifeMD (LFMD – Research Report) and keeping the price target at $12.00. David ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best rising ...

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...

Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...

A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s ...

We recently compiled a list of the 8 Best Momentum Stocks To Invest In Right Now. In this article, we are going to take a ...

The wife of country music star Jelly Roll recently shared that she began using tirzepatide, an antidiabetic medication that was granted FDA approval to treat weight loss. But despite just taking a ...

NHS England has asked NICE to consider approving a slow phased rollout of tirzepatide (Mounjaro) for weight loss in primary care to avoid overwhelming GPs. It follows draft recommendations from NICE ...

NHS England has proposed a phased rollout of tirzepatide, a promising weight-loss drug, to benefit patients most likely to achieve significant clinical outcomes. In the SURMOUNT-4 trial ...